LivaNova PLC (NASDAQ:LIVN) Stock Has Average Price Target of $87.75

LivaNova PLC (NASDAQ:LIVN) has been assigned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $99.56.

LIVN has been the subject of a number of recent research reports. Weiss Ratings upgraded shares of LivaNova from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, October 27th. Mizuho set a $115.00 price objective on shares of LivaNova in a research note on Wednesday. Piper Sandler reaffirmed an “overweight” rating and issued a $90.00 target price (up from $87.00) on shares of LivaNova in a report on Wednesday, September 2nd. Needham & Company LLC upped their target price on shares of LivaNova from $93.00 to $112.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Raymond James Financial set a $120.00 target price on shares of LivaNova in a research note on Wednesday.

Insider Activity

In other LivaNova news, Director Brooke Story sold 2,300 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $81.42, for a total transaction of $187,266.00. Following the completion of the sale, the director directly owned 7,488 shares of the company’s stock, valued at approximately $609,672.96. This trade represents a 23.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Francesco Bianchi sold 3,500 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $78.01, for a total value of $273,035.00. Following the sale, the director directly owned 4,434 shares of the company’s stock, valued at $345,896.34. The trade was a 44.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 7,450 shares of company stock worth $591,839 in the last 90 days. 0.35% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of LIVN. Allworth Financial LP increased its stake in shares of LivaNova by 93.5% during the second quarter. Allworth Financial LP now owns 298 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares during the period. Root Financial Partners LLC purchased a new position in LivaNova during the third quarter worth about $32,000. Farther Finance Advisors LLC raised its holdings in LivaNova by 59.7% during the third quarter. Farther Finance Advisors LLC now owns 452 shares of the company’s stock worth $35,000 after purchasing an additional 169 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new stake in LivaNova in the second quarter valued at about $37,000. Finally, Sterling Capital Management LLC lifted its position in LivaNova by 34.6% in the third quarter. Sterling Capital Management LLC now owns 1,261 shares of the company’s stock valued at $96,000 after purchasing an additional 324 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $91.14 on Tuesday. The stock has a market cap of $5.02 billion, a P/E ratio of 25.81 and a beta of 0.91. LivaNova has a twelve month low of $48.82 and a twelve month high of $99.38. The stock has a 50 day moving average of $79.08 and a two-hundred day moving average of $73.40. The company has a current ratio of 1.46, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, November 4th. The company reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.06 by $0.17. The business had revenue of $393.15 million for the quarter, compared to analyst estimates of $381.13 million. LivaNova had a net margin of 13.01% and a return on equity of 16.10%. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period last year, the firm posted $1.11 earnings per share. On average, research analysts forecast that LivaNova will post 3.78 earnings per share for the current year.

LivaNova News Roundup

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q3 results topped expectations. LivaNova reported adjusted earnings of $1.23 per share, ahead of estimates of about $1.03–$1.06, and revenue of $393.15 million versus roughly $381 million expected. Revenue rose 9.9% year over year. LivaNova Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: 2026 outlook improved. The company forecast revenue growth of 9%–10% and raised its full-year EPS guidance to $4.40–$4.50, signaling confidence in continued growth. LivaNova forecasts 2026 growth and raises EPS guidance
• Positive Sentiment: Analysts raised their targets. Needham lifted its target to $112 from $93 and maintained a Buy rating; Baird raised its target to $111 from $95 and kept an Outperform rating. The revisions reflect more favorable expectations after the results and guidance update. Needham raises LivaNova price target
• Neutral Sentiment: OSA neuromodulation is a potential longer-term opportunity. Coverage highlighted LivaNova’s interest in entering this market, but the articles provided no details on timing, investment, or expected commercial impact. LivaNova eyes OSA neuromodulation entry

About LivaNova

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.